Modifier genes in cystic fibrosis

被引:40
作者
Davies, JC [1 ]
Griesenbach, U
Alton, E
机构
[1] Univ London Imperial Coll Sci & Technol, Dept Gene Therapy, Natl Heart & Lung Inst, Fac Med, London SW3 6LR, England
[2] Royal Brompton Hosp, Dept Paediat Resp Med, London, England
[3] Royal Brompton Hosp, Dept Thorac Med, London, England
关键词
polymorphism; haplotype; lung function; inflammation; phenotype;
D O I
10.1002/ppul.20198
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Although over 1,000 disease-causing mutations in the CFTR gene have been described, the highly variable disease phenotype in cystic fibrosis (CF) cannot be explained on the basis of this gene alone. Both the environment and other non-CFTR genes are likely to be important. The increased understanding of pathophysiological processes in the CF lung has led to several studies on genes in these pathways, including those involved in host defense, mucin production, and airway responsiveness. Additionally, candidate modifiers of the gastrointestinal manifestations of CF have been explored. One of the major aims of such studies is to produce targets for novel drug developments. This review will summarize the field to date and discuss some of the methodological issues important in the design and interpretation of such studies. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:383 / 391
页数:9
相关论文
共 65 条
  • [1] Seeking modifier genes in cystic fibrosis
    Accurso, FJ
    Sontag, MK
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (03) : 289 - 290
  • [2] The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
    Altshuler, D
    Hirschhorn, JN
    Klannemark, M
    Lindgren, CM
    Vohl, MC
    Nemesh, J
    Lane, CR
    Schaffner, SF
    Bolk, S
    Brewer, C
    Tuomi, T
    Gaudet, D
    Hudson, TJ
    Daly, M
    Groop, L
    Lander, ES
    [J]. NATURE GENETICS, 2000, 26 (01) : 76 - 80
  • [3] TGF-β1 genotype and accelerated decline in lung function of patients with cystic fibrosis
    Arkwright, PD
    Laurie, S
    Super, M
    Pravica, V
    Schwarz, MJ
    Webb, AK
    Hutchinson, IV
    [J]. THORAX, 2000, 55 (06) : 459 - 462
  • [4] End-organ dysfunction in cystic fibrosis - Association with angiotensin I converting enzyme and cytokine gene polymorphisms
    Arkwright, PD
    Pravica, V
    Geraghty, PJ
    Super, M
    Webb, AK
    Schwarz, M
    Hutchinson, IV
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (03) : 384 - 389
  • [5] Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.3.CO
  • [6] 2-G
  • [7] HLA-DR polymorphism in allergic bronchopulmonary aspergillosis
    Aron, Y
    Bienvenu, T
    Hubert, D
    Dusser, D
    Dall'Ava, J
    Polla, BS
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (04) : 891 - 892
  • [8] HLA class II polymorphism in cystic fibrosis - A possible modifier of pulmonary phenotype
    Aron, Y
    Polla, BS
    Bienvenu, T
    Dall'Ava, J
    Dusser, D
    Hubert, D
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (05) : 1464 - 1468
  • [9] PROTEASE-ANTIPROTEASE IMBALANCE IN THE LUNGS OF CHILDREN WITH CYSTIC-FIBROSIS
    BIRRER, P
    MCELVANEY, NG
    RUDEBERG, A
    SOMMER, CW
    LIECHTIGALLATI, S
    KRAEMER, R
    HUBBARD, R
    CRYSTAL, RG
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (01) : 207 - 213
  • [10] Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events
    Boekholdt, SM
    Peters, RJG
    de Maat, MPM
    Zwinderman, AH
    van der Wall, EE
    Reitsma, PH
    Jukema, JW
    Kastelein, JJP
    [J]. AMERICAN HEART JOURNAL, 2004, 147 (01) : 181 - 186